Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial

BACKGROUND: Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical studies. METHODOLOGY: We conducted two...

Descripción completa

Detalles Bibliográficos
Autores principales: Barda, Beatrice, Coulibaly, Jean T., Puchkov, Maxim, Huwyler, Jörg, Hattendorf, Jan, Keiser, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026339/
https://www.ncbi.nlm.nih.gov/pubmed/27636542
http://dx.doi.org/10.1371/journal.pntd.0005008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026339/
https://www.ncbi.nlm.nih.gov/pubmed/27636542
http://dx.doi.org/10.1371/journal.pntd.0005008

Ejemplares similares